Novartis Chief: Good Things Come To Those Who Wait

In the company’s third-quarter conference call, Novartis CEO Joe Jimenez admitted that generic competition to its blockbuster Gleevec will continue to drag on the company in 2017. However, he touted a pipeline of 12 potential blockbusters and restructuring efforts over the past three years as evidence that the company will be positioned for growth from 2018.

Novartis AG is headed for an uptick but not for more than a year: that was the message from CEO Joe Jimenez as the company reported its third-quarter results. “The future of this company is not about 2017: it’s about 2018, 2019, 2020,” said Jimenez, responding to questioning by analysts on specific challenges the firm faces, notably the under-performance of its Alcon Inc. eye care division and the ongoing ramp-up in generic competition to its blockbuster drug Gleevec (imatinib), which will face European genericization from December 2016 on top of the existing competition in the US.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By 

Adstiladrin sales hit €70m in first full year on the market

Regulatory And Macroeconomic Uncertainty Hang Over Q1 Earnings Season

 

As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.

US Pharma Tariff Reprieve Appears Short-Lived

 

Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.

Pharma Exhales, Dodging A Financial Blow With Tariff Exemption

 

Industry lobbied for pharmaceuticals to be exempt from Trump’s sweeping US tariffs and the effort appears to have paid off. J&J, Lilly and Merck & Co. even got shout outs.

More from Business

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: Trump’s tariff rollercoaster; regulatory, economic uncertainties hang over Q1 earnings; IPOs rise in Q1 but may slow; Chinese deal-making matures; and AstraZeneca talks about Chinese innovation.

Bristol’s Opdivo + Yervoy Gets FDA Liver, Colorectal Cancer Nods

 
• By 

Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.

Biotech Leaders Ponder Tariff Ramifications

 

Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.